熱門資訊> 正文
结构治疗学任命新的医疗主任
2024-09-18 17:35
- Clinical-stage global biopharmaceutical company Structure Therapeutics (NASDAQ:GPCR) said that Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18.
- Dr. Coll has served as VP of Clinical Development at Structure since 2022.
- In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer.
More on Structure Therapeutics
- Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field
- Seeking Alpha’s Quant Rating on Structure Therapeutics
- Historical earnings data for Structure Therapeutics
- Financial information for Structure Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
